Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML.
Animals
Apoptosis
/ physiology
Cell Line, Tumor
Disease Models, Animal
Humans
Interferon-gamma
/ metabolism
Leukemia, Myeloid, Acute
/ metabolism
Mice
Mice, Inbred C57BL
Nod2 Signaling Adaptor Protein
/ metabolism
Receptors, Pattern Recognition
/ metabolism
Signal Transduction
/ physiology
Tumor Necrosis Factor Receptor Superfamily, Member 7
/ metabolism
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
24
07
2019
accepted:
21
01
2020
pubmed:
26
2
2020
medline:
24
10
2020
entrez:
26
2
2020
Statut:
ppublish
Résumé
TLRs, a family of membrane-bound pattern recognition receptors found on innate immune cells, have been well studied in the context of cancer therapy. Activation of these receptors has been shown to induce inflammatory anticancer events, including differentiation and apoptosis, across a wide variety of malignancies. In contrast, intracellular pattern recognition receptors such as NOD-like receptors have been minimally studied. NOD2 is a member of the NOD-like receptor family that initiates inflammatory signaling in response to the bacterial motif muramyl dipeptide. In this study, we examined the influence of NOD2 in human acute myeloid leukemia (AML) cells, demonstrating that IFN-γ treatment upregulated the expression of NOD2 signaling pathway members SLC15A3 and SLC15A4, downstream signaling kinase RIPK2, and the NOD2 receptor itself. This priming allowed for effective induction of caspase-1-dependent cell death upon treatment with muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic ligand for NOD2. Furthermore, the combination of MTP-PE and IFN-γ on AML blasts generated an inflammatory cytokine profile and activated NK cells. In a murine model of AML, dual treatment with MTP-PE and IFN-γ led to a significant increase in mature CD27
Identifiants
pubmed: 32094205
pii: jimmunol.1900885
doi: 10.4049/jimmunol.1900885
pmc: PMC8176195
mid: NIHMS1704384
doi:
Substances chimiques
NOD2 protein, human
0
Nod2 Signaling Adaptor Protein
0
Receptors, Pattern Recognition
0
Tumor Necrosis Factor Receptor Superfamily, Member 7
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1988-1997Subventions
Organisme : NCI NIH HHS
ID : R01 CA162411
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA203584
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL124325
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197734
Pays : United States
Informations de copyright
Copyright © 2020 by The American Association of Immunologists, Inc.
Références
J Clin Invest. 2016 Dec 1;126(12):4404-4416
pubmed: 27775550
Cancer Immunol Immunother. 2011 May;60(5):671-83
pubmed: 21327636
Clin Immunol Immunopathol. 1997 Aug;84(2):185-93
pubmed: 9245551
EMBO J. 2004 Apr 7;23(7):1587-97
pubmed: 15044951
Nature. 2014 May 8;509(7499):240-4
pubmed: 24695226
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
J Clin Oncol. 2006 Dec 20;24(36):5716-24
pubmed: 17179105
J Am Acad Dermatol. 2004 May;50(5):722-33
pubmed: 15097956
Immunity. 2014 Dec 18;41(6):898-908
pubmed: 25526305
Blood. 2016 May 19;127(20):2427-38
pubmed: 26884374
J Immunol. 2006 Apr 15;176(8):4804-10
pubmed: 16585574
Expert Rev Vaccines. 2005 Jun;4(3):329-50
pubmed: 16026248
J Biol Chem. 2016 Dec 2;291(49):25656-25666
pubmed: 27780867
Leukemia. 1996 Mar;10(3):478-82
pubmed: 8642865
Blood. 2009 Oct 29;114(18):3909-16
pubmed: 19710498
Pediatr Blood Cancer. 2014 Feb;61(2):238-44
pubmed: 23997016
Eur J Clin Pharmacol. 2012 Oct;68(10):1347-55
pubmed: 22460239
Clin Oral Investig. 2015 Jul;19(6):1419-28
pubmed: 25467233
Cardiovasc Ther. 2009 Summer;27(2):117-23
pubmed: 19426249
Haematologica. 2012 Jun;97(6):867-73
pubmed: 22133778
Nature. 2002 Mar 14;416(6877):194-9
pubmed: 11894098
J Am Acad Dermatol. 1999 Dec;41(6):1002-7
pubmed: 10570388
J Immunol. 2009 Apr 1;182(7):4321-7
pubmed: 19299732
Cell Immunol. 1997 Mar 15;176(2):127-34
pubmed: 9073385
Nature. 2001 May 31;411(6837):603-6
pubmed: 11385577
J Immunol. 1987 Jun 15;138(12):4185-91
pubmed: 3108384
Exp Ther Med. 2017 Oct;14(4):2911-2916
pubmed: 28966674
FEBS Lett. 2008 Apr 2;582(7):1044-8
pubmed: 18319062
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7803-8
pubmed: 18511561
Eur J Immunol. 2001 Mar;31(3):792-801
pubmed: 11241284
Nucleic Acids Res. 2016 Jan 4;44(D1):D917-24
pubmed: 26507857
Nat Immunol. 2016 Aug 19;17(9):1025-36
pubmed: 27540992
Clin Cancer Res. 2016 Apr 15;22(8):1914-21
pubmed: 26787753
Br Med J. 1976 Nov 20;2(6046):1222-5
pubmed: 791447
Curr Cancer Drug Targets. 2006 Mar;6(2):123-33
pubmed: 16529542
Blood. 2007 Jan 1;109(1):323-30
pubmed: 16940427
Clin Immunol. 2017 Jan;174:63-72
pubmed: 27876460
Cancer Immunol Immunother. 1987;25(1):47-53
pubmed: 3109737
Nature. 2001 May 31;411(6837):599-603
pubmed: 11385576
Blood. 2014 Feb 6;123(6):894-904
pubmed: 24363398
Front Immunol. 2018 Mar 01;9:389
pubmed: 29545802
Immunotherapy. 2009 Nov;1(6):949-64
pubmed: 20563267
J Biol Chem. 1998 Dec 4;273(49):32608-13
pubmed: 9829999
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3725-9
pubmed: 8097322
J Exp Med. 1999 Nov 15;190(10):1375-82
pubmed: 10562313
Eur J Immunol. 2008 Jan;38(1):184-91
pubmed: 18157816
Cell. 1995 Jun 2;81(5):801-9
pubmed: 7774019
J Clin Oncol. 2010 Feb 20;28(6):955-9
pubmed: 20085940
J Intern Med. 2000 Sep;248(3):171-83
pubmed: 10971784
Front Immunol. 2017 May 29;8:573
pubmed: 28611767
J Immunol. 2015 Sep 15;195(6):2580-90
pubmed: 26246143
Blood. 2013 Aug 15;122(7):1316-24
pubmed: 23744585
Neuro Oncol. 2006 Jan;8(1):60-6
pubmed: 16443949
Immunol Rev. 2008 Apr;222:357-68
pubmed: 18364014
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
PLoS One. 2009;4(4):e4931
pubmed: 19337385
J Immunother. 2012 May;35(4):299-308
pubmed: 22495387
Target Oncol. 2018 Oct;13(5):583-598
pubmed: 30229471
Bibl Haematol. 1975;(40):737-49
pubmed: 1057948
Mol Cell. 2012 Jun 29;46(6):746-58
pubmed: 22607974
Cancer Chemother Pharmacol. 1986;18(1):63-8
pubmed: 3093108
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):141-6
pubmed: 16373510
Br J Haematol. 2002 Jun;117(4):821-7
pubmed: 12060116
N Engl J Med. 1991 Oct 24;325(17):1205-9
pubmed: 1922207
Blood. 2003 Aug 15;102(4):1389-96
pubmed: 12714493
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Blood. 2011 Sep 22;118(12):3273-9
pubmed: 21791425
Nat Med. 2007 May;13(5):552-9
pubmed: 17479101
Clin Exp Immunol. 1990 May;80(2):241-6
pubmed: 2357852
J Biol Chem. 2001 Feb 16;276(7):4812-8
pubmed: 11087742
J Neurosci. 2000 Jun 15;20(12):4398-404
pubmed: 10844008
Blood. 2009 May 28;113(22):5488-96
pubmed: 19234143
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Blood. 2012 Aug 2;120(5):1130-6
pubmed: 22674806
Am J Cancer Res. 2016 Feb 15;6(3):677-89
pubmed: 27152244
Biotechnol Healthc. 2007 Oct;4(5):14-5
pubmed: 22478671
Science. 2005 Feb 4;307(5710):731-4
pubmed: 15692051
Br J Cancer. 1988 Sep;58(3):368-72
pubmed: 3179190
Immunology. 2011 Jul;133(3):350-9
pubmed: 21506999